Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Ansbert Gadicke. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Ansbert Gadicke har rapporteret besiddelser eller handler i følgende virksomheder:
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Ansbert Gadicke. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb AVTX / Avalo Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AVTX / Avalo Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CGEM / Cullinan Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CGEM / Cullinan Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-09-01 | CGEM | GADICKE ANSBERT | 790 | 29,4700 | 790 | 29,4700 | 23.281 | 252 | 7.3100 | -17.506 | -75,19 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb HOWL / Werewolf Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-05-04 | HOWL | GADICKE ANSBERT | 245.000 | 16,0000 | 245.000 | 16,0000 | 3.920.000 | 59 | 20.3100 | 1.055.950 | 26,94 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg HOWL / Werewolf Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-27 | HOWL | GADICKE ANSBERT | 4.386 | 1,0500 | 4.386 | 1,0500 | 4.605 | 11 | 0.6300 | -1.842 | -40,00 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb HSTOQ / Histogen Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg HSTOQ / Histogen Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb PCRX / Pacira BioSciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg PCRX / Pacira BioSciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RPTX / Repare Therapeutics Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-06-23 | RPTX | GADICKE ANSBERT | 500.000 | 20,0000 | 500.000 | 20,0000 | 10.000.000 | 198 | 44.46 | 12.230.000 | 122,30 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RPTX / Repare Therapeutics Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-03-12 | RPTX | GADICKE ANSBERT | 695.000 | 28,1800 | 695.000 | 28,1800 | 19.585.100 | 364 | 12.2100 | -11.099.150 | -56,67 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2017-10-10 | RYTM | MPM BIOVENTURES V, L.P. | 100.000 | 17,0000 | 100.000 | 17,0000 | 1.700.000 | 268 | 35.85 | 1.885.000 | 110,88 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SNDX / Syndax Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SNDX / Syndax Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TRDA / Entrada Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-11-02 | TRDA | MPM BioVentures 2014, L.P. | 100.000 | 20,0000 | 100.000 | 20,0000 | 2.000.000 | 15 | 35 | 1.500.000 | 75,00 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TRDA / Entrada Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VSTM / Verastem, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VSTM / Verastem, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Ansbert Gadicke som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-05-15 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | -1.031.931 | 3.452.797 | -23,01 | 8,06 | -8.317.364 | 27.829.544 | |
2025-04-30 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | -4.386 | 6.718.670 | -0,07 | 1,05 | -4.605 | 7.054.604 | |
2025-04-30 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
X - Other | 50.873 | 6.723.056 | 0,76 | 0,09 | 4.579 | 605.075 | |
2024-12-12 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Common Stock |
S - Sale | -21.787 | 4.381.062 | -0,49 | 20,23 | -440.751 | 88.628.884 | |
2024-12-12 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Common Stock |
S - Sale | -22.935 | 4.402.849 | -0,52 | 20,77 | -476.360 | 91.447.174 | |
2023-06-05 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
J - Other | -3.370.982 | 0 | -100,00 | ||||
2023-06-05 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
J - Other | -3.854.963 | 0 | -100,00 | ||||
2023-06-05 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
J - Other | -304.001 | 0 | -100,00 | ||||
2023-05-24 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
S - Sale | -70.170 | 304.001 | -18,75 | 1,88 | -131.920 | 571.522 | |
2023-05-24 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
X - Other | 178.269 | 374.171 | 91,00 | 0,74 | 131.919 | 276.887 | |
2023-02-10 |
|
5 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
M - Exercise | 350.938 | 595.489 | 143,50 | 4,30 | 1.509.033 | 2.560.603 | |
2022-08-01 |
|
4 | ALVR |
Allovir, Inc.
Common Stock |
A - Award | 3.253.796 | 16.674.766 | 24,24 | 4,61 | 15.000.000 | 76.870.671 | |
2022-05-19 |
|
4 | ALVR |
Allovir, Inc.
Stock Option (Right to Buy) |
A - Award | 27.500 | 27.500 | |||||
2022-03-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Stock Option (Right to Buy) |
A - Award | 7.800 | 7.800 | |||||
2022-01-06 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | -30.347 | 4.484.728 | -0,67 | 42,03 | -1.275.484 | 188.493.118 | |
2022-01-06 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | -12.829 | 4.515.075 | -0,28 | 46,47 | -596.164 | 209.815.535 | |
2022-01-06 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | -11.318 | 4.527.904 | -0,25 | 45,32 | -512.932 | 205.204.609 | |
2022-01-06 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | -32.396 | 4.539.222 | -0,71 | 43,20 | -1.399.507 | 196.094.390 | |
2022-01-06 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | -158.579 | 4.571.618 | -3,35 | 42,05 | -6.668.247 | 192.236.537 | |
2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -2.499 | 4.730.197 | -0,05 | 34,11 | -85.241 | 161.347.020 |
2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -30.059 | 4.732.696 | -0,63 | 33,15 | -996.456 | 156.888.872 |
2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -100 | 4.762.755 | 0,00 | 35,04 | -3.504 | 166.886.935 |
2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -850 | 4.762.855 | -0,02 | 34,08 | -28.968 | 162.318.098 |
2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.960 | 4.763.705 | -0,04 | 33,57 | -65.797 | 159.917.577 |
2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -14.173 | 4.765.665 | -0,30 | 32,35 | -458.497 | 154.169.263 |
2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -300 | 4.779.838 | -0,01 | 36,26 | -10.878 | 173.316.926 |
2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -4.047 | 4.780.138 | -0,08 | 35,44 | -143.426 | 169.408.091 |
2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -29.402 | 4.784.185 | -0,61 | 34,68 | -1.019.661 | 165.915.536 |
2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -12.434 | 4.813.587 | -0,26 | 34,83 | -433.076 | 167.657.235 |
2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -49.796 | 4.826.021 | -1,02 | 33,74 | -1.680.117 | 162.829.949 |
2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.500 | 4.875.817 | -0,03 | 35,34 | -53.010 | 172.311.373 |
2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -9.131 | 4.877.317 | -0,19 | 34,61 | -316.024 | 168.803.941 |
2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.111 | 4.886.448 | -0,21 | 33,82 | -341.954 | 165.259.671 |
2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -46.992 | 4.896.559 | -0,95 | 35,19 | -1.653.648 | 172.309.911 |
2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -9.809 | 4.943.551 | -0,20 | 34,62 | -339.588 | 171.145.736 |
2021-11-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -500 | 4.953.360 | -0,01 | 35,37 | -17.685 | 175.200.343 |
2021-11-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -16.856 | 4.953.860 | -0,34 | 34,46 | -580.858 | 170.710.016 |
2021-11-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.258 | 4.970.716 | -0,21 | 36,03 | -369.596 | 179.094.897 |
2021-11-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.952 | 4.980.974 | -0,22 | 35,49 | -388.686 | 176.774.767 |
2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -21.965 | 4.991.926 | -0,44 | 37,02 | -813.144 | 184.801.101 |
2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -30.696 | 5.013.891 | -0,61 | 36,05 | -1.106.591 | 180.750.771 |
2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -8.147 | 5.044.587 | -0,16 | 35,20 | -286.774 | 177.569.462 |
2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -600 | 5.052.734 | -0,01 | 36,50 | -21.900 | 184.424.791 |
2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -32.876 | 5.053.334 | -0,65 | 36,21 | -1.190.440 | 182.981.224 |
2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -19.758 | 5.086.210 | -0,39 | 37,81 | -747.050 | 192.309.600 |
2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -15.575 | 5.105.986 | -0,30 | 37,16 | -578.767 | 189.738.440 |
2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
J - Other | -15.671 | 5.121.543 | -0,31 | ||||
2021-11-04 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -3.683.241 | 0 | -100,00 | ||||
2021-11-04 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -27.617.675 | 0 | -100,00 | ||||
2021-11-04 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Common Stock |
P - Purchase | 100.000 | 4.425.784 | 2,31 | 20,00 | 2.000.000 | 88.515.680 | |
2021-11-04 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Common Stock |
C - Conversion | 509.024 | 4.325.784 | 13,34 | ||||
2021-11-04 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Common Stock |
C - Conversion | 3.816.760 | 3.816.760 | |||||
2021-10-18 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.320 | 5.137.214 | -0,20 | 27,14 | -280.085 | 139.423.988 |
2021-10-18 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.413 | 5.147.534 | -0,07 | 28,01 | -95.598 | 144.182.427 |
2021-10-18 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -14.882 | 5.150.947 | -0,29 | 27,53 | -409.701 | 141.805.571 |
2021-10-14 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -45.719 | 5.165.829 | -0,88 | 27,30 | -1.248.129 | 141.027.132 |
2021-10-14 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -35.023 | 5.211.548 | -0,67 | 27,13 | -950.174 | 141.389.297 |
2021-10-14 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -14.260 | 5.246.571 | -0,27 | 27,09 | -386.303 | 142.129.608 |
2021-10-12 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -81.684 | 5.260.831 | -1,53 | 27,24 | -2.225.072 | 143.305.036 |
2021-10-12 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.400 | 5.342.515 | -0,06 | 27,01 | -91.834 | 144.301.330 |
2021-10-12 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.922 | 5.345.915 | -0,04 | 27,00 | -51.894 | 144.339.705 |
2021-10-05 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -34.659 | 5.347.837 | -0,64 | 27,06 | -937.873 | 144.712.469 |
2021-10-05 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -11.471 | 5.382.496 | -0,21 | 27,00 | -309.717 | 145.327.392 |
2021-09-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.836 | 5.393.967 | -0,07 | 27,00 | -103.572 | 145.637.109 |
2021-09-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -32.154 | 5.397.803 | -0,59 | 27,00 | -868.158 | 145.740.681 |
2021-09-27 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -19.455 | 5.429.957 | -0,36 | 27,09 | -527.036 | 147.097.535 |
2021-09-27 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -8.221 | 5.449.412 | -0,15 | 27,81 | -228.626 | 151.548.148 |
2021-09-27 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.200 | 5.457.633 | -0,02 | 28,38 | -34.056 | 154.887.625 |
2021-09-27 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -60.600 | 5.458.833 | -1,10 | 27,96 | -1.694.376 | 152.628.971 |
2021-09-23 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -23.921 | 5.519.433 | -0,43 | 27,54 | -658.784 | 152.005.185 |
2021-09-23 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -32.858 | 5.543.354 | -0,59 | 27,47 | -902.609 | 152.275.934 |
2021-09-20 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -3.124 | 7.648.268 | -0,04 | 29,06 | -90.783 | 222.258.668 |
2021-09-20 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -432 | 244.551 | -0,18 | 29,06 | -12.554 | 7.106.652 |
2021-09-20 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -22.930 | 5.576.212 | -0,41 | 27,84 | -638.371 | 155.241.742 |
2021-09-20 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -17.743 | 5.599.142 | -0,32 | 27,03 | -479.593 | 151.344.808 |
2021-09-20 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -76.473 | 5.616.885 | -1,34 | 28,82 | -2.203.952 | 161.878.626 |
2021-09-20 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -35.565 | 5.693.358 | -0,62 | 28,47 | -1.012.536 | 162.089.902 |
2021-09-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -6.425 | 7.651.392 | -0,08 | 29,16 | -187.353 | 223.114.591 |
2021-09-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -888 | 244.983 | -0,36 | 29,16 | -25.894 | 7.143.704 |
2021-09-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -7.106 | 7.657.817 | -0,09 | 29,17 | -207.282 | 223.378.522 |
2021-09-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -982 | 245.871 | -0,40 | 29,17 | -28.645 | 7.172.057 |
2021-09-16 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.659 | 5.728.923 | -0,03 | 28,15 | -46.701 | 161.269.182 |
2021-09-16 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -38.677 | 5.730.582 | -0,67 | 27,79 | -1.074.834 | 159.252.874 |
2021-09-16 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.063 | 5.769.259 | -0,10 | 27,99 | -169.703 | 161.481.559 |
2021-09-16 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -30.018 | 5.775.322 | -0,52 | 27,50 | -825.495 | 158.821.355 |
2021-09-13 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -3.595 | 7.664.923 | -0,05 | 29,10 | -104.614 | 223.049.259 |
2021-09-13 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -497 | 246.853 | -0,20 | 29,10 | -14.463 | 7.183.422 |
2021-09-13 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -5.931 | 7.668.518 | -0,08 | 29,04 | -172.236 | 222.693.763 |
2021-09-13 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -820 | 247.350 | -0,33 | 29,04 | -23.813 | 7.183.044 |
2021-09-13 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -13.727 | 7.674.449 | -0,18 | 29,35 | -402.887 | 225.245.078 |
2021-09-13 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.898 | 248.170 | -0,76 | 29,35 | -55.706 | 7.283.790 |
2021-09-13 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -35.785 | 5.805.340 | -0,61 | 27,64 | -989.097 | 160.459.598 |
2021-09-13 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -11.330 | 5.841.125 | -0,19 | 28,73 | -325.511 | 167.815.521 |
2021-09-13 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -11.313 | 5.852.455 | -0,19 | 27,86 | -315.180 | 163.049.396 |
2021-09-13 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -38.028 | 5.863.768 | -0,64 | 28,97 | -1.101.671 | 169.873.359 |
2021-09-08 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -10.842 | 7.688.176 | -0,14 | 29,11 | -315.611 | 223.802.803 |
2021-09-08 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.499 | 250.068 | -0,60 | 29,11 | -43.636 | 7.279.479 |
2021-09-08 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -25.067 | 7.699.018 | -0,32 | 29,04 | -727.946 | 223.579.483 |
2021-09-08 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -3.465 | 251.567 | -1,36 | 29,04 | -100.624 | 7.305.506 |
2021-09-08 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -12.731 | 7.724.085 | -0,16 | 29,60 | -376.838 | 228.632.916 |
2021-09-08 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.760 | 255.032 | -0,69 | 29,60 | -52.096 | 7.548.947 |
2021-09-08 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.573 | 5.901.796 | -0,03 | 29,10 | -45.774 | 171.742.264 |
2021-09-08 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -18.663 | 5.903.369 | -0,32 | 28,61 | -533.948 | 168.895.387 |
2021-09-08 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
J - Other | -31.340 | 5.922.032 | -0,53 | ||||
2021-09-08 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -50.996 | 5.953.372 | -0,85 | 29,18 | -1.488.063 | 173.719.395 |
2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -15.757 | 7.736.816 | -0,20 | 29,46 | -464.201 | 227.926.599 |
2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -2.178 | 256.792 | -0,84 | 29,46 | -64.164 | 7.565.092 |
2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -5.714 | 7.752.573 | -0,07 | 29,47 | -168.392 | 228.468.326 |
2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | -790 | 258.970 | -0,30 | 29,47 | -23.281 | 7.631.846 | |
2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.553 | 7.758.287 | -0,02 | 30,14 | -46.807 | 233.834.770 |
2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -215 | 259.760 | -0,08 | 30,14 | -6.480 | 7.829.166 |
2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.285 | 7.759.840 | -0,02 | 29,43 | -37.818 | 228.372.091 |
2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -177 | 259.975 | -0,07 | 29,43 | -5.209 | 7.651.064 |
2021-08-31 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -31.001 | 7.761.125 | -0,40 | 29,30 | -908.329 | 227.400.962 |
2021-08-31 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -4.285 | 260.152 | -1,62 | 29,30 | -125.550 | 7.622.454 |
2021-08-31 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -13.357 | 7.792.126 | -0,17 | 29,09 | -388.555 | 226.672.945 |
2021-08-31 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.846 | 264.437 | -0,69 | 29,09 | -53.700 | 7.692.472 |
2021-08-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.713 | 7.805.483 | -0,02 | 29,09 | -49.831 | 227.061.500 |
2021-08-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -237 | 266.283 | -0,09 | 29,09 | -6.894 | 7.746.172 |
2021-08-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -50.882 | 7.807.196 | -0,65 | 29,48 | -1.500.001 | 230.156.138 |
2021-08-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -7.025 | 266.520 | -2,57 | 29,48 | -207.097 | 7.857.010 |
2021-08-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -53.359 | 7.858.018 | -0,67 | 29,11 | -1.553.280 | 228.746.904 |
2021-08-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -7.376 | 273.545 | -2,63 | 29,11 | -214.715 | 7.962.895 |
2021-08-12 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -2.510 | 7.911.377 | -0,03 | 29,05 | -72.916 | 229.825.502 |
2021-08-12 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -347 | 280.921 | -0,12 | 29,05 | -10.080 | 8.160.755 |
2021-07-13 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -711 | 3.882.485 | -0,02 | 34,10 | -24.245 | 132.392.738 |
2021-07-13 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -57.301 | 3.883.196 | -1,45 | 33,58 | -1.924.168 | 130.397.722 |
2021-07-13 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -4.067 | 3.940.497 | -0,10 | 33,06 | -134.455 | 130.272.831 |
2021-06-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -2.700 | 3.944.564 | -0,07 | 33,29 | -89.883 | 131.314.536 |
2021-06-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -2.700 | 3.947.264 | -0,07 | 34,82 | -94.014 | 137.443.732 |
2021-06-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -13.800 | 3.949.964 | -0,35 | 34,06 | -470.028 | 134.535.774 |
2021-06-28 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -22.567 | 3.963.764 | -0,57 | 33,51 | -756.220 | 132.825.732 |
2021-06-28 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -6.121 | 3.986.331 | -0,15 | 33,53 | -205.237 | 133.661.678 |
2021-06-23 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -1.410 | 3.992.452 | -0,04 | 32,98 | -46.502 | 131.671.067 |
2021-06-23 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -429 | 3.993.862 | -0,01 | 34,09 | -14.625 | 136.150.756 |
2021-06-23 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -3.371 | 3.994.291 | -0,08 | 33,36 | -112.457 | 133.249.548 |
2021-06-23 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -31.788 | 3.997.662 | -0,79 | 34,63 | -1.100.818 | 138.439.035 |
2021-06-23 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -5.800 | 4.029.450 | -0,14 | 33,80 | -196.040 | 136.195.410 |
2021-06-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -3.199 | 4.035.250 | -0,08 | 34,03 | -108.862 | 137.319.558 |
2021-06-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -5.801 | 4.038.449 | -0,14 | 33,46 | -194.101 | 135.126.504 |
2021-06-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -1.708 | 4.044.250 | -0,04 | 34,12 | -58.277 | 137.989.810 |
2021-06-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -30.810 | 4.045.958 | -0,76 | 33,78 | -1.040.762 | 136.672.461 |
2021-06-16 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -4.227 | 4.076.768 | -0,10 | 33,33 | -140.886 | 135.878.677 |
2021-06-16 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -2.000 | 4.080.995 | -0,05 | 33,09 | -66.180 | 135.040.125 |
2021-06-10 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -24.368 | 4.082.995 | -0,59 | 34,79 | -847.763 | 142.047.396 |
2021-06-10 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -10.862 | 4.107.363 | -0,26 | 34,42 | -373.870 | 141.375.434 |
2021-06-10 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -17.155 | 4.118.225 | -0,41 | 33,41 | -573.149 | 137.589.897 |
2021-06-10 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -9.045 | 4.135.380 | -0,22 | 32,80 | -296.676 | 135.640.464 |
2021-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -19.017 | 4.144.425 | -0,46 | 32,96 | -626.800 | 136.600.248 |
2021-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -1.700 | 4.163.442 | -0,04 | 32,25 | -54.825 | 134.271.004 |
2021-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -2.400 | 4.165.142 | -0,06 | 30,74 | -73.776 | 128.036.465 |
2021-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -4.694 | 4.167.542 | -0,11 | 31,28 | -146.828 | 130.360.714 |
2021-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -8.042 | 4.172.236 | -0,19 | 30,80 | -247.694 | 128.504.869 |
2021-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -22.296 | 4.180.278 | -0,53 | 31,92 | -711.688 | 133.434.474 |
2021-06-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -297 | 4.202.574 | -0,01 | 32,42 | -9.629 | 136.247.449 |
2021-06-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -5.918 | 4.202.871 | -0,14 | 31,83 | -188.370 | 133.777.384 |
2021-06-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -15.141 | 4.208.789 | -0,36 | 32,50 | -492.082 | 136.785.642 |
2021-06-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -16.742 | 4.223.930 | -0,39 | 32,67 | -546.961 | 137.995.793 |
2021-06-02 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -25.118 | 6.328.095 | -0,40 | 20,50 | -514.919 | 129.725.948 |
2021-06-02 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -18.491 | 6.353.213 | -0,29 | 20,44 | -377.956 | 129.859.674 |
2021-06-02 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -100 | 6.371.704 | 0,00 | 22,60 | -2.260 | 144.000.510 |
2021-06-02 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.100 | 6.371.804 | -0,05 | 21,92 | -67.952 | 139.669.944 |
2021-06-02 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.685 | 6.374.904 | -0,17 | 20,88 | -223.103 | 133.107.996 |
2021-05-27 |
|
4 | ALVR |
Allovir, Inc.
Stock Option (Right to Buy) |
A - Award | 22.500 | 22.500 | |||||
2021-05-27 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -13.961 | 6.385.589 | -0,22 | 20,26 | -282.850 | 129.372.033 |
2021-05-27 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.198 | 6.399.550 | -0,05 | 20,04 | -64.088 | 128.246.982 |
2021-05-27 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -3.624 | 4.240.672 | -0,09 | 33,16 | -120.172 | 140.620.684 |
2021-05-27 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -4.327 | 4.244.296 | -0,10 | 32,81 | -141.969 | 139.255.352 |
2021-05-27 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -1.704 | 4.248.623 | -0,04 | 33,01 | -56.249 | 140.247.045 |
2021-05-27 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -22.332 | 4.250.327 | -0,52 | 32,74 | -731.150 | 139.155.706 |
2021-05-27 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -100 | 4.272.659 | 0,00 | 33,59 | -3.359 | 143.518.616 |
2021-05-27 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -6.472 | 4.272.759 | -0,15 | 32,87 | -212.735 | 140.445.588 |
2021-05-24 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -5.000 | 6.402.748 | -0,08 | 20,12 | -100.600 | 128.823.290 |
2021-05-24 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.907 | 6.407.748 | -0,17 | 20,21 | -220.430 | 129.500.587 |
2021-05-24 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -18.653 | 4.279.231 | -0,43 | 34,28 | -639.425 | 146.692.039 |
2021-05-24 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -3.547 | 4.297.884 | -0,08 | 33,30 | -118.115 | 143.119.537 |
2021-05-24 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -302.669 | 4.301.431 | -6,57 | 34,80 | -10.532.881 | 149.689.799 |
2021-05-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -11.713 | 6.418.655 | -0,18 | 20,34 | -238.242 | 130.555.443 |
2021-05-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -17.833 | 6.430.368 | -0,28 | 20,39 | -363.615 | 131.115.204 |
2021-05-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -18.402 | 6.448.201 | -0,28 | 20,67 | -380.369 | 133.284.315 |
2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -600 | 4.604.100 | -0,01 | 35,19 | -21.114 | 162.018.279 |
2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -9.357 | 4.604.700 | -0,20 | 34,66 | -324.314 | 159.598.902 |
2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -4.400 | 4.614.057 | -0,10 | 35,00 | -154.000 | 161.491.995 |
2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -9.143 | 4.618.457 | -0,20 | 34,23 | -312.965 | 158.089.783 |
2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -21.834 | 4.627.600 | -0,47 | |||
2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -90 | 4.649.434 | 0,00 | 35,14 | -3.163 | 163.381.111 |
2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -8.541 | 4.649.524 | -0,18 | 34,61 | -295.604 | 160.920.026 |
2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -14.773 | 4.658.065 | -0,32 | 33,90 | -500.805 | 157.908.404 |
2021-05-17 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -4.666 | 6.466.603 | -0,07 | 20,07 | -93.647 | 129.784.722 |
2021-05-17 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.900 | 6.471.269 | -0,11 | 20,04 | -138.276 | 129.684.231 |
2021-05-17 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -4.855 | 6.478.169 | -0,07 | 20,06 | -97.391 | 129.952.070 |
2021-05-12 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -29.684 | 6.483.024 | -0,46 | 20,53 | -609.413 | 133.096.483 |
2021-05-12 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -7.672 | 6.512.708 | -0,12 | 21,51 | -165.025 | 140.088.349 |
2021-05-12 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -13.773 | 6.520.380 | -0,21 | 20,96 | -288.682 | 136.667.165 |
2021-05-12 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -411 | 6.534.153 | -0,01 | 22,46 | -9.231 | 146.757.076 |
2021-05-12 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -16.722 | 6.534.564 | -0,26 | 21,78 | -364.205 | 142.322.804 |
2021-05-06 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -59 | 6.551.286 | 0,00 | 23,09 | -1.362 | 151.269.194 |
2021-05-06 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.113 | 6.551.345 | -0,15 | 22,52 | -227.745 | 147.536.289 |
2021-05-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -12.899.925 | 0 | -100,00 | ||||
2021-05-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -38.817.998 | 0 | -100,00 | ||||
2021-05-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
P - Purchase | 245.000 | 6.672.183 | 3,81 | 16,00 | 3.920.000 | 106.754.928 | |
2021-05-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
C - Conversion | 1.488.033 | 6.427.183 | 30,13 | ||||
2021-05-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
C - Conversion | 4.477.742 | 4.939.150 | 970,45 | ||||
2021-05-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.500 | 6.561.458 | -0,05 | 23,33 | -81.655 | 153.078.815 |
2021-05-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -26.230 | 6.564.958 | -0,40 | 23,03 | -604.077 | 151.190.983 |
2021-05-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -4.401 | 6.591.188 | -0,07 | 23,45 | -103.203 | 154.563.359 |
2021-05-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -26.365 | 6.595.589 | -0,40 | 23,03 | -607.186 | 151.896.415 |
2021-05-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -268.023 | 6.621.954 | -3,89 | 22,35 | -5.990.314 | 148.000.672 |
2021-04-29 | 3 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
461.408 | ||||||||
2021-04-29 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -21.781 | 6.889.977 | -0,32 | 22,54 | -490.944 | 155.300.082 |
2021-04-29 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -45.511 | 6.911.758 | -0,65 | 22,02 | -1.002.152 | 152.196.911 |
2021-04-29 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -36.803 | 6.957.269 | -0,53 | 22,01 | -810.034 | 153.129.491 |
2021-04-29 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -14.219 | 6.994.072 | -0,20 | 21,64 | -307.699 | 151.351.718 |
2021-04-29 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -8.328 | 7.008.291 | -0,12 | 21,26 | -177.053 | 148.996.267 |
2021-04-29 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.501 | 7.016.619 | -0,05 | 20,99 | -73.486 | 147.278.833 |
2021-04-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -555 | 7.020.120 | -0,01 | 19,48 | -10.811 | 136.751.938 |
2021-04-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -8.417 | 7.020.675 | -0,12 | 18,94 | -159.418 | 132.971.584 |
2021-04-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -834 | 7.029.092 | -0,01 | 19,09 | -15.921 | 134.185.366 |
2021-04-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -21.415 | 7.029.926 | -0,30 | 18,70 | -400.460 | 131.459.616 |
2021-04-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -100 | 7.051.341 | 0,00 | 20,08 | -2.008 | 141.590.927 |
2021-04-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -9.956 | 7.051.441 | -0,14 | 19,29 | -192.051 | 136.022.297 |
2021-04-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -300 | 7.061.397 | 0,00 | 20,56 | -6.168 | 145.182.322 |
2021-04-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -5.547 | 7.061.697 | -0,08 | 19,82 | -109.942 | 139.962.835 |
2021-04-15 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -8.696 | 7.067.244 | -0,12 | 20,49 | -178.181 | 144.807.830 |
2021-04-15 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -12.806 | 7.075.940 | -0,18 | 20,83 | -266.749 | 147.391.830 |
2021-04-15 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.000 | 7.088.746 | -0,01 | 20,06 | -20.060 | 142.200.245 |
2021-04-15 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -2.362 | 7.089.746 | -0,03 | 20,08 | -47.429 | 142.362.100 |
2021-04-15 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -13.692 | 7.092.108 | -0,19 | 19,35 | -264.940 | 137.232.290 |
2021-04-13 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -400 | 7.105.800 | -0,01 | 22,68 | -9.072 | 161.159.544 |
2021-04-13 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.700 | 7.106.200 | -0,09 | 21,52 | -144.184 | 152.925.424 |
2021-04-13 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -13.528 | 7.112.900 | -0,19 | 20,72 | -280.300 | 147.379.288 |
2021-04-13 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.300 | 7.126.428 | -0,14 | 23,67 | -243.801 | 168.682.551 |
2021-04-13 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -200 | 6.004.368 | 0,00 | 29,99 | -5.998 | 180.070.996 |
2021-04-09 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -414 | 6.004.568 | -0,01 | 31,01 | -12.838 | 186.201.654 |
2021-04-09 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -31.890 | 6.004.982 | -0,53 | 30,51 | -972.964 | 183.212.001 |
2021-04-09 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
J - Other | -15.670 | 6.036.872 | -0,26 | ||||
2021-04-09 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.300 | 6.052.542 | -0,02 | 33,84 | -43.992 | 204.818.021 |
2021-04-09 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.083 | 6.053.842 | -0,05 | 32,84 | -101.246 | 198.808.171 |
2021-04-09 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -5.295 | 6.056.925 | -0,09 | 32,07 | -169.811 | 194.245.585 |
2021-03-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 24.271 | 4.672.838 | 0,52 | ||||
2021-03-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | -695.000 | 4.697.109 | -12,89 | 28,18 | -19.585.100 | 132.364.532 | |
2021-02-12 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -183.051 | 3.238.306 | -5,35 | 20,00 | -3.661.020 | 64.766.120 |
2021-02-09 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -9.400 | 3.421.357 | -0,27 | 20,25 | -190.350 | 69.282.479 |
2021-02-09 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -72.128 | 3.430.757 | -2,06 | 20,04 | -1.445.445 | 68.752.370 |
2021-02-09 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.172 | 3.502.885 | -0,29 | 20,01 | -203.542 | 70.092.729 |
2021-02-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -29.730 | 3.513.057 | -0,84 | 20,37 | -605.600 | 71.560.971 |
2021-02-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -41.922 | 3.542.787 | -1,17 | 20,21 | -847.244 | 71.599.725 |
2021-02-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -48.421 | 3.584.709 | -1,33 | 20,13 | -974.715 | 72.160.192 |
2021-01-27 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -706.825 | 3.633.130 | -16,29 | 20,00 | -14.136.500 | 72.662.600 |
2021-01-27 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.363 | 4.339.955 | -0,03 | 21,08 | -28.732 | 91.486.251 |
2021-01-27 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -13.006 | 4.341.318 | -0,30 | 21,23 | -276.117 | 92.166.181 |
2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -24.695 | 4.354.324 | -0,56 | 21,72 | -536.375 | 94.575.917 |
2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -200 | 4.379.019 | 0,00 | 23,77 | -4.754 | 104.089.282 |
2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -4.887 | 4.379.219 | -0,11 | 22,61 | -110.495 | 99.014.142 |
2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -20.979 | 4.384.106 | -0,48 | 22,11 | -463.846 | 96.932.584 |
2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
J - Other | X | -101.646 | 4.405.085 | -2,26 | |||
2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -2.000 | 4.506.731 | -0,04 | 24,71 | -49.420 | 111.361.323 |
2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -15.694 | 4.508.731 | -0,35 | 23,95 | -375.871 | 107.984.107 |
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -649.030 | 0 | -100,00 | ||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -2.276.692 | 0 | -100,00 | ||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3.551.640 | 0 | -100,00 | ||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series Seed Convertible Preferred Stock |
C - Conversion | -1.136.525 | 0 | -100,00 | ||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Common Stock |
P - Purchase | 300.000 | 7.913.887 | 3,94 | 21,00 | 6.300.000 | 166.191.627 | |
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Common Stock |
C - Conversion | 649.030 | 7.613.887 | 9,32 | ||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Common Stock |
C - Conversion | 2.276.692 | 6.964.857 | 48,56 | ||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Common Stock |
C - Conversion | 3.551.640 | 4.688.165 | 312,50 | ||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Common Stock |
C - Conversion | 1.136.525 | 1.136.525 | |||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Stock Option (Right to Buy) |
J - Other | 88.824 | 88.824 | |||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Stock Option (Right to Buy) |
J - Other | 262.114 | 262.114 | |||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series C Convertible Preferred Stock |
J - Other | 649.030 | 649.030 | |||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series B Convertible Preferred Stock |
J - Other | 2.276.692 | 2.276.692 | |||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series A Convertible Preferred Stock |
J - Other | 3.551.640 | 3.551.640 | |||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series Seed Convertible Preferred Stock |
J - Other | 1.136.525 | 1.136.525 | |||||
2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Common Stock |
J - Other | 281.268 | 281.268 | |||||
2021-01-07 | 3 | CGEM |
Cullinan Management, Inc.
Common Stock |
281.268 | ||||||||
2020-10-21 |
|
4/A | ITOS |
iTeos Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 16.608 | 0 | -100,00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series B Preferred Stock |
C - Conversion | 700.453 | 0 | -100,00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series B Preferred Stock |
C - Conversion | 775.975 | 0 | -100,00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series A-1 Preferred Stock |
C - Conversion | 1.525.348 | 0 | -100,00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series A-1 Preferred Stock |
C - Conversion | 1.783.879 | 0 | -100,00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 151.224 | 2.377.025 | 6,79 | 15,00 | 2.268.360 | 35.655.375 | |
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 173.776 | 2.849.453 | 6,49 | 15,00 | 2.606.640 | 42.741.795 | |
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 700.453 | 2.225.801 | 45,92 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 775.975 | 2.675.677 | 40,85 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 1.525.348 | 1.525.348 | |||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 1.783.879 | 1.899.702 | 1.540,18 | ||||
2020-10-01 | 3 | ONCR |
Oncorus, Inc.
Common Stock |
115.823 | ||||||||
2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -26.176 | 0 | -100,00 | ||||
2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -70.492 | 0 | -100,00 | ||||
2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1.326.313 | 0 | -100,00 | ||||
2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -275.932 | 0 | -100,00 | ||||
2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -743.076 | 0 | -100,00 | ||||
2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -13.980.992 | 0 | -100,00 | ||||
2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Common Stock |
C - Conversion | 91.081 | 91.081 | |||||
2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Common Stock |
C - Conversion | 245.279 | 245.279 | |||||
2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Common Stock |
C - Conversion | 4.614.943 | 4.614.943 | |||||
2020-08-05 |
|
4 | ALVR |
Allovir, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -20.000.000 | 0 | -100,00 | ||||
2020-08-05 |
|
4 | ALVR |
Allovir, Inc.
Common Stock |
C - Conversion | 13.420.970 | 13.420.970 | |||||
2020-07-31 |
|
4 | ALVR |
Allovir, Inc.
Stock Option (Right to Buy) |
A - Award | 22.500 | 22.500 | |||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2.600.628 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -29.440 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -79.281 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -1.491.666 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -81.295 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -157.529 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2.361.805 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -4.211.330 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -47.674 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -128.384 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -2.415.530 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -131.645 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -255.094 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -3.824.591 | 0 | -100,00 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 160.000 | 2.355.557 | 7,29 | 19,00 | 3.040.000 | 44.755.583 | |
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 1.121 | 25.974 | 4,51 | 19,00 | 21.299 | 493.506 | |
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 3.020 | 69.951 | 4,51 | 19,00 | 57.380 | 1.329.069 | |
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 56.814 | 1.316.139 | 4,51 | 19,00 | 1.079.466 | 25.006.641 | |
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 3.096 | 71.727 | 4,51 | 19,00 | 58.824 | 1.362.813 | |
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 5.994 | 138.985 | 4,51 | 19,00 | 113.886 | 2.640.715 | |
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 89.955 | 2.083.887 | 4,51 | 19,00 | 1.709.145 | 39.593.853 | |
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 797.983 | 2.195.557 | 57,10 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 9.033 | 24.853 | 57,10 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 24.326 | 66.931 | 57,10 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 457.706 | 1.259.325 | 57,10 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 24.944 | 68.381 | 57,43 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 48.336 | 132.991 | 57,10 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 724.702 | 1.993.932 | 57,10 | ||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 1.397.574 | 1.397.574 | |||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 15.820 | 15.820 | |||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 42.605 | 42.605 | |||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 801.619 | 801.619 | |||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 43.687 | 43.687 | |||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 84.655 | 84.655 | |||||
2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 1.269.230 | 1.269.230 | |||||
2020-07-29 | 3 | ALVR |
Allovir, Inc.
Common Stock |
60.394 | ||||||||
2020-07-29 | 3 | ALVR |
Allovir, Inc.
Common Stock |
60.394 | ||||||||
2020-07-29 | 3 | ALVR |
Allovir, Inc.
Common Stock |
60.394 | ||||||||
2020-07-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 16.608 | 0 | -100,00 | ||||
2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -1.288.948 | 0 | -100,00 | ||||
2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class A Preferred Shares |
C - Conversion | -3.603.161 | 0 | -100,00 | ||||
2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
P - Purchase | 500.000 | 5.392.109 | 10,22 | 20,00 | 10.000.000 | 107.842.180 | |
2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 1.288.948 | 4.892.109 | 35,77 | ||||
2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 3.603.161 | 3.603.161 | |||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series B Preferred Stock |
C - Conversion | -1.750.000 | 0 | -100,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series B Preferred Stock |
C - Conversion | -217.500 | 0 | -100,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series B Preferred Stock |
C - Conversion | -1.586.623 | 0 | -100,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series B Preferred Stock |
C - Conversion | -105.825 | 0 | -100,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series B Preferred Stock |
C - Conversion | -32.500 | 0 | -100,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series B Preferred Stock |
C - Conversion | -57.552 | 0 | -100,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series A Preferred Stock |
C - Conversion | -15.000.000 | 0 | -100,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series A Preferred Stock |
C - Conversion | -2.174.998 | 0 | -100,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series A Preferred Stock |
C - Conversion | -13.599.621 | 0 | -100,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series A Preferred Stock |
C - Conversion | -907.073 | 0 | -100,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series A Preferred Stock |
C - Conversion | -325.002 | 0 | -100,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series A Preferred Stock |
C - Conversion | -493.306 | 0 | -100,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
P - Purchase | 1.373.333 | 1.569.235 | 701,03 | 15,00 | 20.599.995 | 23.538.525 | |
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 282.540 | 2.704.315 | 11,67 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 35.115 | 386.270 | 10,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 256.163 | 2.451.844 | 11,67 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 17.085 | 163.532 | 11,67 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 5.247 | 57.716 | 10,00 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 9.291 | 88.935 | 11,67 | ||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 2.421.775 | 2.421.775 | |||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 351.155 | 351.155 | |||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 2.195.681 | 2.195.681 | |||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 146.447 | 146.447 | |||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 52.469 | 52.469 | |||||
2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 79.644 | 79.644 | |||||
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy) |
X - Other | -101.675 | 0 | -100,00 | ||||
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy) |
X - Other | -152.514 | 0 | -100,00 | ||||
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy) |
X - Other | -50.837 | 0 | -100,00 | ||||
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy) |
X - Other | -171.579 | 0 | -100,00 | ||||
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy) |
X - Other | -57.192 | 0 | -100,00 | ||||
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy) |
X - Other | -25.418 | 0 | -100,00 | ||||
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -835.705 | 0 | -100,00 | ||||
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -3.157.506 | 0 | -100,00 | ||||
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3.050.329 | 0 | -100,00 | ||||
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
P - Purchase | 500.000 | 8.422.847 | 6,31 | 14,00 | 7.000.000 | 117.919.858 | |
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | -1.971 | 7.922.847 | -0,02 | 14,00 | -27.594 | 110.919.858 | |
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
X - Other | 559.215 | 7.924.818 | 7,59 | 0,05 | 27.513 | 389.901 | |
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
C - Conversion | 835.705 | 7.365.603 | 12,80 | ||||
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
C - Conversion | 3.157.506 | 6.529.898 | 93,63 | ||||
2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
C - Conversion | 3.050.329 | 3.372.392 | 947,12 | ||||
2019-02-13 | 3 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
391.804 | ||||||||
2019-02-13 | 3 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
391.804 | ||||||||
2019-02-13 | 3 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
391.804 | ||||||||
2019-02-07 | 3 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
644.126 | ||||||||
2019-02-07 | 3 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
644.126 | ||||||||
2019-02-07 | 3 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
644.126 | ||||||||
2017-10-11 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A-1 Junior Preferred Stock |
C - Conversion | -15.887.703 | 0 | -100,00 | ||||
2017-10-11 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A Preferred Stock |
C - Conversion | -7.651.831 | 0 | -100,00 | ||||
2017-10-11 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 100.000 | 2.696.392 | 3,85 | 17,00 | 1.700.000 | 45.838.664 | |
2017-10-11 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 2.567.014 | 2.596.392 | 8.737,88 | ||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
2017-02-22 |
|
4 | RDUS |
Radius Health, Inc.
Stock Option (Right to Buy) |
A - Award | 27.500 | 27.500 | |||||
2016-09-29 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
J - Other | -1.943.751 | 3.887.502 | -33,33 | ||||
2016-06-13 |
|
4 | CHMA |
CHIASMA, INC
Stock Option (Right to Buy) |
A - Award | 10.000 | 10.000 | |||||
2016-06-02 |
|
4 | RDUS |
Radius Health, Inc.
Stock Option (Right to Buy) |
A - Award | 27.500 | 27.500 | |||||
2016-03-09 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -312.085 | 0 | -100,00 | ||||
2016-03-09 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -718.396 | 0 | -100,00 | ||||
2016-03-09 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock |
C - Conversion | -1.138.210 | 0 | -100,00 | ||||
2016-03-09 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 312.085 | 2.168.691 | 16,81 | ||||
2016-03-09 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 718.396 | 1.856.606 | 63,12 | ||||
2016-03-09 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 1.138.210 | 1.138.210 | |||||
2016-02-12 |
|
4 | RDUS |
Radius Health, Inc.
Stock Option (Right to Buy) |
A - Award | 27.500 | 27.500 | |||||
2015-10-20 |
|
4 | CERC |
Cerecor Inc.
Series B Convertible Preferred Stock |
C - Conversion | -16.672.224 | 0 | -100,00 | ||||
2015-10-20 |
|
4 | CERC |
Cerecor Inc.
Common Stock |
C - Conversion | 595.436 | 595.436 | |||||
2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Series E Preferred Stock |
C - Conversion | -13.000.000 | 0 | -100,00 | ||||
2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Series D' Preferred Stock |
C - Conversion | -16.066.669 | 0 | -100,00 | ||||
2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Series C' Preferred Stock |
C - Conversion | -22.721.988 | 0 | -100,00 | ||||
2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Series B-1' Preferred Stock |
C - Conversion | -95.225 | 0 | -100,00 | ||||
2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Common Stock |
C - Conversion | 1.423.566 | 5.681.544 | 33,43 | ||||
2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Common Stock |
C - Conversion | 1.759.381 | 4.257.978 | 70,41 | ||||
2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Common Stock |
C - Conversion | 2.488.171 | 2.498.597 | 23.865,06 | ||||
2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Common Stock |
C - Conversion | 10.426 | 10.426 | |||||
2015-05-26 |
|
4 | RDUS |
Radius Health, Inc.
Stock Option (Right to Buy) |
A - Award | 15.000 | 15.000 | |||||
2014-12-19 |
|
4 | RDUS |
Radius Health, Inc.
Stock Option (Right to Buy) |
A - Award | 30.000 | 30.000 | |||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -184.242 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -114.537 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -71.638 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -859 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -3.511 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -4.346 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.468 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -1.340 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -5.477 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -6.779 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -2.291 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -3.752 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -15.327 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -18.975 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -6.414 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -44.395 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -181.364 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -224.528 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -75.899 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -2.985 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -12.194 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -15.096 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -5.103 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 2.141.547 | 2.141.547 | |||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 59.445 | 59.445 | |||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 92.734 | 92.734 | |||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 259.567 | 259.567 | |||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 3.071.454 | 3.071.454 | |||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 206.506 | 206.506 | |||||
2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Warrant to Purchase Common Stock (Right to Buy) |
C - Conversion | 37.369 | 37.369 | |||||
2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Warrant to Purchase Series D Preferred Stock (Right to Buy) |
C - Conversion | -1.516.122 | 0 | -100,00 | ||||
2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -10.266.940 | 0 | -100,00 | ||||
2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -15.400.411 | 0 | -100,00 | ||||
2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -2.947.605 | 0 | -100,00 | ||||
2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -6.000.000 | 0 | -100,00 | ||||
2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -20.757.635 | 0 | -100,00 | ||||
2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 253.066 | 1.776.692 | 16,61 | ||||
2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 379.599 | 1.523.626 | 33,18 | ||||
2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 114.942 | 1.144.027 | 11,17 | ||||
2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 230.756 | 1.029.085 | 28,90 | ||||
2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 798.329 | 798.329 | |||||
2014-03-12 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -600.000 | 2.751.048 | -17,90 | 20,02 | -12.012.000 | 55.075.981 | |
2014-03-11 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -26.713 | 0 | -100,00 | 20,16 | -538.534 | ||
2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | 37.117 | 37.117 | |||||
2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | 12.247 | 12.393 | 8.388,36 | ||||
2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | 15.310 | 17.937 | 582,79 | ||||
2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | 20.876 | 22.767 | 1.103,97 | ||||
2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | 20.876 | 22.767 | 1.103,97 | ||||
2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | 20.876 | 38.386 | 119,22 | ||||
2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | -1.000.000 | 3.351.048 | -22,98 | ||||
2014-02-11 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
S - Sale | -466.666 | 2.413.819 | -16,20 | 29,25 | -13.649.980 | 70.604.206 | |
2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Warrant to Purchase Common Stock (Right to Buy) |
C - Conversion | 32.220 | 32.220 | |||||
2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Warrant to Purchase Series B Preferred Stock (Right to Buy) |
C - Conversion | -265.837 | 0 | -100,00 | ||||
2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Series B Convertible Preferred Stock |
C - Conversion | -8.333.334 | 0 | -100,00 | ||||
2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Common Stock |
P - Purchase | 165.265 | 1.192.080 | 16,09 | 11,00 | 1.817.915 | 13.112.880 | |
2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Common Stock |
J - Other | 16.716 | 1.026.815 | 1,65 | 11,00 | 183.876 | 11.294.965 | |
2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Common Stock |
C - Conversion | 1.010.099 | 1.010.099 | |||||
2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Series C Preferred Stock |
C - Conversion | -375.000 | 0 | -100,00 | ||||
2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Series B Preferred Stock |
C - Conversion | -1.333.333 | 0 | -100,00 | ||||
2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Series A Preferred Stock |
C - Conversion | -4.000.000 | 0 | -100,00 | ||||
2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
P - Purchase | 500.000 | 4.351.050 | 12,98 | 6,00 | 3.000.000 | 26.106.300 | |
2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
C - Conversion | 225.631 | 3.851.050 | 6,22 | ||||
2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
C - Conversion | 802.246 | 3.625.419 | 28,42 | ||||
2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
C - Conversion | 2.406.739 | 2.823.173 | 577,94 | ||||
2013-06-26 | 3 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
180.505 | ||||||||
2013-06-06 |
|
4 | EPZM |
Epizyme, Inc.
Series B Preferred Stock |
C - Conversion | -1.176.472 | 0 | -100,00 | ||||
2013-06-06 |
|
4 | EPZM |
Epizyme, Inc.
Series A Preferred Stock |
C - Conversion | -6.930.000 | 0 | -100,00 | ||||
2013-06-06 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
C - Conversion | 392.156 | 2.880.485 | 15,76 | ||||
2013-06-06 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
C - Conversion | 2.309.998 | 2.488.329 | 1.295,34 | ||||
2013-05-30 | 3 | EPZM |
Epizyme, Inc.
Common Stock |
178.331 | ||||||||
2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Common Stock Warrant |
A - Award | 179.095 | 179.095 | |||||
2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Series B Convertible Preferred Stock |
A - Award | 71.638 | 71.638 | 61,42 | 4.400.006 | 4.400.006 | ||
2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Common Stock Warrant |
A - Award | 3.670 | 3.670 | |||||
2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Series B Convertible Preferred Stock |
A - Award | 1.468 | 1.468 | 61,42 | 90.165 | 90.165 | ||
2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Common Stock Warrant |
A - Award | 5.728 | 5.728 | |||||
2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Series B Convertible Preferred Stock |
A - Award | 2.291 | 2.291 | 61,42 | 140.713 | 140.713 | ||
2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Common Stock Warrant |
A - Award | 16.035 | 16.035 | |||||
2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Series B Convertible Preferred Stock |
A - Award | 6.414 | 6.414 | 61,42 | 393.948 | 393.948 | ||
2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Common Stock Warrant |
A - Award | 189.748 | 189.748 | |||||
2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Series B Convertible Preferred Stock |
A - Award | 75.899 | 75.899 | 61,42 | 4.661.717 | 4.661.717 | ||
2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Common Stock Warrant |
A - Award | 12.758 | 12.758 | |||||
2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Series B Convertible Preferred Stock |
A - Award | 5.103 | 5.103 | 61,42 | 313.426 | 313.426 | ||
2013-03-13 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -500.000 | 2.790.479 | -15,20 | 27,86 | -13.930.000 | 77.742.745 | |
2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Series D Preferred Stock |
C - Conversion | -275.539 | 0 | -100,00 | ||||
2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -337.622 | 0 | -100,00 | ||||
2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Series B-2 Preferred Stock |
C - Conversion | -1.949.879 | 0 | -100,00 | ||||
2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 313.527 | 2.632.928 | 13,52 | ||||
2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 369.522 | 2.319.401 | 18,95 | ||||
2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 1.949.879 | 1.949.879 | |||||
2012-07-10 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -1.624.574 | 1.275.886 | -56,01 | 0,31 | -498.744 | 391.697 | |
2012-07-10 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -671.217 | 2.900.460 | -18,79 | 0,29 | -195.324 | 844.034 | |
2012-07-05 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -98.210 | 3.571.677 | -2,68 | 0,29 | -28.481 | 1.035.786 | |
2012-07-05 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -80.348 | 3.669.887 | -2,14 | 0,29 | -23.301 | 1.064.267 | |
2012-07-02 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -19.500 | 3.750.235 | -0,52 | 0,29 | -5.655 | 1.087.568 | |
2012-06-21 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -12.000 | 3.759.735 | -0,32 | 0,29 | -3.480 | 1.090.323 | |
2012-06-19 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -1.450 | 3.781.735 | -0,04 | 0,29 | -420 | 1.096.703 | |
2012-06-07 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -8.400 | 3.783.185 | -0,22 | 0,29 | -2.436 | 1.097.124 | |
2012-06-07 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -29.555 | 3.791.585 | -0,77 | 0,29 | -8.571 | 1.099.560 | |
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -29.850 | 3.821.140 | -0,78 | 0,30 | -8.955 | 1.146.342 | |
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -51.007 | 3.850.990 | -1,31 | 0,30 | -15.302 | 1.155.297 | |
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -15.300 | 3.901.997 | -0,39 | 0,30 | -4.622 | 1.178.793 | |
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -293.015 | 3.917.297 | -6,96 | 0,30 | -87.904 | 1.175.189 | |
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -135.250 | 4.210.312 | -3,11 | 0,30 | -40.629 | 1.264.778 | |
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -287.000 | 4.345.562 | -6,20 | 0,30 | -86.990 | 1.317.140 | |
2012-03-08 |
|
4 | VSTM |
Verastem, Inc.
Stock Option (Right to Buy) |
A - Award | 12.500 | 12.500 | |||||
2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Series C Preferred Stock |
C - Conversion | -266.666 | 0 | -100,00 | ||||
2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Series B Preferred Stock |
C - Conversion | -2.500.000 | 0 | -100,00 | ||||
2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Series A Preferred Stock |
C - Conversion | -4.000.000 | 0 | -100,00 | ||||
2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Common Stock |
P - Purchase | 3.740 | 3.740 | 10,00 | 37.400 | 37.400 | ||
2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Common Stock |
P - Purchase | 96.260 | 2.029.593 | 4,98 | 10,00 | 962.600 | 20.295.930 | |
2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Common Stock |
C - Conversion | 76.190 | 1.933.333 | 4,10 | ||||
2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Common Stock |
C - Conversion | 714.286 | 1.857.143 | 62,50 | ||||
2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Common Stock |
C - Conversion | 1.142.857 | 1.142.857 |